Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16638507 | 0.99 | L3MBTL1 (0.57) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9967740 | 0.89 | SMN1; SMN2 (0.61) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A | |
| SCHEMBL256091 | 0.85 | L3MBTL1 (0.61) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL256088 | 0.84 | L3MBTL1 (0.60) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL9967741 | 0.82 | TDP1 (0.58) | L3MBTL1ALDH1A1KMT2AMEN1POLB | |
| SCHEMBL10239972 | 0.80 | RORC (0.67) | RAB9AALDH1A1KMT2AMAPTMEN1 | |
| SCHEMBL30088674 | 0.80 | L3MBTL1 (0.55) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL38657757 | 0.76 | MAPT (0.60) | L3MBTL1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL16638505 | 0.75 | ALDH1A1 (0.55) | SMN1; SMN2ALDH1A1KMT2AHTTMEN1 | |
| SCHEMBL257067 | 0.74 | SMN1; SMN2 (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | BAYER IP GMBH (DE) | 2015-06-25 | — | — | US | disclosed |
| US-9006265-B2 | Substituted fused pyrimidinones and dihydropyrimidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150173359-A1 | SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES | DHPS, FDPS, DPYD | L3MBTL1 3190/4885NPC1 4035/4885RAB9A 783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.